Commentaries & PR – EAS FH Studies Collaboration

Latest from the FHSC registry: take action now for universal cholesterol screening in early life

Commentary to publication: Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study. The Lancet; https://doi.org/10.1016/S0140-6736(23)01842-1. Familial hypercholesterolaemia (FH) is the most common inherited lipid disorder, affecting about one in 300 people worldwide (1). If untreated, elevated low-density lipoprotein cholesterol (LDL‑C) levels from birth confer an increased risk of premature atherosclerotic cardiovascular disease. … Read more

Global FHSC registry makes the case for universal cholesterol screening of children for familial hypercholesterolaemia

December 13, 2023 – Gothenburg, Sweden Finding children with familial hypercholesterolaemia (FH), the most common inherited lipid disorder, relies on family cascade screening, usually after a parent or relative has a heart attack, as physical signs of FH in children are uncommon, meaning that detection is delayed in most. These were the key findings from … Read more

Homozygous familial hypercholesterolaemia: new hope for getting patients to goal?

Management of homozygous familial hypercholesterolaemia is challenging. What are the prospects for attaining LDL cholesterol goal with novel therapies? This latest commentary discusses the new findings for evinacumab, an ANGPTL3 monoclonal antibody. The European Atherosclerosis Society (EAS) continues to be a key player in familial hypercholesterolaemia (FH), raising awareness and supporting research to promote early … Read more

HICC registry: levelling up access to treatment urgently needed

Commentary to publication: Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. The Lancet; https://doi.org/10.1016/S0140-6736(21)02001-8. Familial hypercholesterolaemia (FH) is an inherited condition characterised by markedly elevated low-density lipoprotein cholesterol (LDL-C) levels from birth, which if undiagnosed and untreated, confer an increased risk of premature atherosclerotic cardiovascular disease. The most severe presentation is homozygous FH, estimated … Read more

FHSC new publication in The Lancet – highlighting the challenges of FH

September 07, 2021 – Gothenburg, Sweden First data from the European Atherosclerosis Society (EAS) Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry of over 42,000 individuals from 56 countries, provides a unique snapshot into the worldwide burden and challenges of FH care. Detection needs to be earlier, with greater use of intensive lipid-lowering therapy, including combination … Read more

Improving FH care: first survey data from EAS FHSC

2019-04-26 Five years ago, the European Atherosclerosis Society (EAS) was a trailblazer in highlighting the underdiagnosis and undertreatment of familial hypercholesterolaemia (FH, inherited high cholesterol) in a Consensus Panel initiative.1 This was followed by subsequent statements, specifically focusing on homozygous FH,2 and importantly, FH in children and adolescents.3 Supported by other international evidence,4-7 the EAS recognised the worldwide lack … Read more